Topic: cell manufacturing
Seeing an opportunity, Japan’s Fujifilm will build a U.S. stem cell manufacturing facility not only for its own efforts but also as a CDMO.
With about $225 million in hand from the IPO, Orchard Therapeutics is starting on a plant in California for its gene therapy candidates.
Abzena will invest $20 million in a cell manufacturing facility, and Catalent is spending $2.5 million on a clinical supply facility in China.
Astellas will invest $255 million in production and R&D as it pushes into gene and cell therapies for cancer and other diseases.
Another cell manufacturing facility will be built in the U.S., this by a transatlantic biotech in which GlaxoSmithKline owns a sizable share.
Novartis is looking ahead to China for introduction of its CAR-T treatment Kymriah with a deal for manufacturing there.
Novartis’ traditional pill manufacturing will shoulder the brunt of a cost-cutting effort announced Tuesday as it looks to a future in biologic drugs.
Biotech Rubius Therapeutics will invest large chunk of its recently raised $220 million to build a manufacturing facility.
Atara Biotherapeutics has initiated construction of a new CAR-T gene therapy manufacturing facility.
Lonza opened the world’s biggest manufacturing plant for cell and gene therapies targeting rare genetic disorders or life-threatening diseases.